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A B S T R A C TObjectives: The main objectives were to estimate the cost-effectiveness
and budget impact of indacaterol (a once-daily, long-acting-beta2-agonist)
compared with 1) salmeterol/fluticasone, 2) formoterol/budesonide, and
3) tiotropium for the treatment of chronic obstructive pulmonary disease
in Colombia. Methods: A Markov model was utilized to simulate the
progressive course of chronic obstructive pulmonary disease, distin-
guished by forced expiratory volume in 1 second predicted according to
the four Global Initiative for Chronic Obstructive Lung Disease severity
stages by using prebronchodilation values. Efficacy was based on the
initial improvement in forced expiratory volume in 1 second, taken from
either a network meta-analysis (salmeterol/fluticasone and formoterol/
budesonide) or a randomized controlled trial (tiotropium). Colombian
direct costs and life tables were incorporated in the adaptation, and
analysis was performed from a health care payer perspective, discount-
ing future costs (presented as US dollars) and benefits at 5%. A budget
impact model was built to estimate the cost impact of indacaterol in
Colombia over 3 and 5 years. Results: Indacaterol was found to bent matter Copyright & 2012, International Society
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.1016/j.vhri.2012.09.003
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Argentina.dominant (i.e., less costly and more effective) against both salmeterol/
fluticasone and formoterol/budesonide per life year and quality-adjusted
life-year gained after a 5-year time horizon. The average cost saving
against salmeterol/fluticasone and formoterol/budesonide was US $411
and US $909 per patient, respectively. All probabilistic sensitivity analysis
simulations indicated indacaterol to be less costly than salmeterol/
fluticasone and formoterol/budesonide. Indacaterol was more effective
and more costly than tiotropium, corresponding to an incremental cost-
utility ratio of US $2584 per quality-adjusted life-year. Conclusions: The
results indicate that by replacing salmeterol/fluticasone or formoterol/
budesonide with indacaterol, there are possible cost savings for the
Colombian health care system. This was demonstrated by both cost-
effectiveness and budget impact models.
Keywords: Colombia, COPD, cost-effectiveness, indacaterol.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Background
Chronic obstructive pulmonary disease (COPD) is a chronic
disease affecting 8.9% [1] of the 14,958,285 [2] Colombians aged
40 years or older. Of these, 31% [1] belong to Global Initiative for
Chronic Obstructive Lung Disease (GOLD) spirometric classification 2
to 4, as defined by GOLD [3]. In 2005, COPDwas ranked as Colombia’s
seventh most disabling disease, with 9.8 disability-adjusted life-
years per patient, and second or third when considering people
older than 80 years and between 60 and 79 years old, respectively [4].
This proves that COPD is a major burden to the Colombian health
care system. It has been estimated that the weighted average cost of
COPD could be US $848.10 per patient per year in Colombia [5]. By
using this average per-patient cost, the burden of COPD was found
to be US $916 million in 2004, based on a COPD prevalence figure of
1,080,000 patients, and US $1129 million, based on 2012 projections
of COPD prevalence, which estimate 1,331,000 patients [2]. This isapproximately 0.7% to 0.9% of the Colombian gross domestic
product (GDP). About 35% of these costs are related to hospitaliza-
tions to treat acute exacerbations [6]. It is unclear whether this
estimate includes the cost of long-acting inhaled therapies used as
maintenance therapy in COPD. An alternative source indicates that
the annual spending on inhaled therapies—long-acting beta2-ago-
nist (LABA), long-acting muscarinic antagonist, and LABA with
inhaled corticosteroids (ICSs)—for COPD in Colombia is estimated
to be US $5.5 million (0.6% of the total cost of COPD), using data
validated by Dr. Luis F. Giraldo [7], with LABA/ICS products being the
market leaders (60% market share in COPD).
There are currently four long-acting inhaled products used in
the treatment of COPD in Colombia: indacaterol 150 mg; a once-
daily LABA, tiotropium 18 mg; a long-acting muscarinic antago-
nist; and two fixed-dose combinations (FDCs) of LABA and ICS:
salmeterol/fluticasone 50/500 mg and formoterol/budesonide
9/320 mg. For the purposes of the current analysis, FDCs werefor Pharmacoeconomics and Outcomes Research (ISPOR).
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frequently used in GOLD stages 2 to 4. It should be noted,
however, that ICSs are not recommended for patients at low risk
of COPD exacerbations, such as those with % predicted forced
expiratory volume in 1 second (FEV1) of more than 50% and with
zero or one exacerbation in the previous year by the current
GOLD strategy [3]. Currently, no long-acting therapies have been
included in the Colombian health benefit plan, despite the
recommendation in the GOLD strategy. Currently, patients with
COPD in Colombia must have their prescriptions approved by the
health service on a case-by-case basis.
The decision of whether to include long-acting inhaled pro-
ducts in the national health plan, and if so which products might
offer the best value for money, would pose a challenging question
to Colombian decision makers. Different tools exist to facilitate the
decision-making process on resource allocation, and one such tool
is the cost-effectiveness (CE) analysis; it is highly suitable as it
considers both the difference in effects gained (i.e., life years [LYs]
or quality-adjusted life-years [QALYs]) and costs incurred between
two interventions. Another commonly used tool is the budget
impact model, which considers the changes in the health care
budget when introducing a new therapy. Both tools have therefore
been utilized numerous times to evaluate the CE and budget impact
of therapies in COPD such as long-acting muscarinic antagonist or
LABA alone, or the latter in combination with ICS. To the authors’
knowledge, however, this is the first COPD CE study in a Latin
American setting and the first CE evaluation of indacaterol com-
pared with a combination of LABA and ICS. A CE analysis will help
decision makers who are considering individual patient applica-
tions for long-acting inhaled products to treat COPD; it may also
help to reconsider the case decision to include certain long-acting
inhaled products in the Colombian Health Benefit Plan, thereby
eliminating the need to assess patients on a case-by-case basis.Methods
The CE analysis was performed by using a Markov model
constructed in Microsoft Excel 2007, with 3-month cycles. The
structure was identical to the model previously published by
Price et al. [5] (Fig. 1). Health states were categorized by the ratio
of prebronchodilator FEV1 compared with that of the general
population. The states were separated according to the GOLD
spirometric classification [8]: mild (GOLD 1: 80%–100%), moderate
(GOLD 2: 50%–80%), severe (GOLD 3: 30%–50%), and very severe
COPD (GOLD 4:o30%) airflow limitation. The initial distributionFig. 1 – Model structure. GOLD, Global Initiative for Chronic
Obstructive Lung Disease.of disease severity in the model corresponded to the baseline
characteristics observed in the Novartis Indacaterol phase III
trial (INHANCE) (1.4%, 42.2%, 45.4%, and 11.0% from stage 1 to 4,
respectively) [9]. To ensure that the model results were represen-
tative of the Colombian population, a disease severity distribution
based on Colombian data was investigated as a scenario analysis
based on the Colombian COPD cohort PREPOCOL [1]. Prediction of
FEV1 for the general population was done by utilizing a regression
model published by Falaschetti et al. [10]; this was used as no
Colombian-specific regression model was available. Each GOLD
state in the model could be further subdivided into no exacerba-
tion, nonsevere exacerbation (not requiring hospitalization),
severe exacerbation (requiring hospitalization), and those having
discontinued therapy. A 7% annual discontinuation rate of ther-
apy was assumed, equal for all treatments.
The annual decline in lung function was 54 ml obtained from
the OLIN study [11], which gives the rate of decline in prebronch-
odilator FEV1. Normal lung function was compared against the
lung function predicted by the annual rate of decline for patients
with COPD to yield a percentage of predicted lung function for each
year. The number of years it took for the percentage predicted
value to cross the threshold of a GOLD class was taken as the
median time for patients to progress one GOLD class. The median
time was then converted into a probability of progressing by using
the following equation: 1  0.5^(1/(median time)).
Two different CE analyses were performed, the first against
formoterol/budesonide 9/320 mg and the second against salmeterol/
fluticasone 50/500 mg. Because there were no head-to-head trials
between indacaterol and LABA/ICS, efficacy was instead based on a
published network meta-analysis (NMA) [12]. This NMA used
Bayesian statistics to compare all therapies linked in the network
at once, considering both direct (i.e., head-to-head trials) and
indirect evidence (i.e., via a common comparator) [13]. The NMA
included 15 placebo-controlled randomized clinical trials of which
13 contained active treatments of interest: indacaterol 150 mg (n ¼ 5
studies), formoterol/budesonide 9/320 mg (n ¼ 3), salmeterol/fluti-
casone 50/500 mg (n ¼ 5), excluding those with only an Asian study
population. The present analysis uses FEV1 results reported in the
NMA publication: indacaterol 150 mg increased FEV1 with 180 ml
(95% credible interval [CrI] 110–250 ml) after 12 weeks; the corre-
sponding number for formoterol/budesonide 9/320 mg was 90 ml
(95% CrI 10–160 ml) and 150 ml (95% CrI 100–230 ml) for salmeterol/
fluticasone 50/500 mg (Table 1). The outcome presented above was
adjusted for two covariates: the proportion of current smokers and
the proportion with severe or very severe COPD. This set of results
from the NMA was selected to ensure that the model could
properly account for the patient characteristics that would have
an impact on the results.
A second analysis was based on the clinical study INHANCE [9],
a head-to-head trial of indacaterol versus open-label tiotropium 18
mg, applying the transition matrix published by Price et al. [5].
No exacerbation data were available from the NMA; thus, only
FEV1 was considered in this analysis; however, exacerbation rates
were included in the analysis versus tiotropium. These were
taken from the INHANCE study. The baseline rate of exacerba-
tions from the placebo arm of the trial was 0.72 per patient-year
[9]. Rate ratios were applied to the baseline rate of exacerbation:
0.67 (95% CI 0.46–0.99) and 0.70 (95% CI 0.48–1.03) for indacaterol
and tiotropium, respectively. As the exacerbation rates by disease
severity (i.e., GOLD stage) were not available, the same rate of
exacerbations per year was applied to all four disease severity
groups. The impact of such an assumption was tested in a
scenario by applying values from a systematic review [14].
Exacerbations were further classified as severe or nonsevere.
Exacerbations requiring hospitalizations were considered severe.
The distribution of severe to nonsevere exacerbations was derived
for each disease severity group on the basis of INHANCE [9].
Table 1 – Model efficacy inputs.
Difference vs. placebo
(Based on NMA) [15] (Based on trial) [9]
Ind 150 lg Sal/Flu For/Bud Ind 150 lg Tio 18 lg
FEV1 change from baseline to 12 wk (95% CrI)
No adjustment 180 ml (160–210) 140 ml (120–160) 90 ml (70–110) 180 ml (148–215) 140 ml (105–180)
Adjusting for covariates 180 ml (110–250) 150 ml (100–230) 90 ml (10–160)
Exacerbations† 0.67 0.67 0.67 0.67 0.70
COPD, chronic obstructive pulmonary disease; Crl, credible interval; FEV1, forced expiratory volume in 1 s; For/Bud, formoterol/budesonide;
Ind, indacaterol; NMA, network meta-analysis; Sal/Flu, salmeterol/fluticasone; Tio, tiotropium.
* Adjusting for proportion of smokers and proportion of patients with severe and very severe COPD.
† Risk ratio compared with placebo.
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stage was based on data used in a previously published model by
Rutten-van Molken [15]. These rates described all-cause mortality
for patients with COPD. In the current analysis, it was assumed
that the majority of recorded deaths would be due to respiratory
disease–related causes. However, age-specific mortality was con-
sidered by the inclusion of all-cause mortality. This was based on
Colombian interim life tables published by the Departamento
Administrativo Nacional de Estadistica [16].
The indacaterol clinical trial program collected health utilities
by using the EuroQoL five-dimensional (EQ-5D) questionnaire. EQ-
5D questionnaire index scores were prepared by using the UK ‘‘York
Tariff’’ [17]. Mean values from these studies were analyzed to
provide model inputs, and the variation around the mean was
used to inform sensitivity analyses. EQ-5D questionnaire results
were summarized by disease severity status to yield a mean utility
weight for each disease severity class as shown in Table 2 [5].
Utility values from the literature were tested as a scenario analysis.
These came from a utility study in patients with COPD conducted
by Stahl et al. [18], who valued health state utilities for each of the
disease severity classes as defined by prebronchodilator FEV1
values. In addition, utility decrements associated with exacerba-
tions were taken from a publication by Rutten-van Molken et al.
[19]. Exacerbation decrements were applied only in the exacerba-
tion states, and the decrement takes place within that cycle only.
Three types of direct costs were considered in the model
analysis: 1) drug acquisition cost, 2) cost of maintenance therapy,Table 2 – Utility values applied per GOLD stage and
disutility for exacerbation.
Ind trials
(CI) [5]
Literature,
mean  SD [18]
Utility per health state
Mild COPD 0.82 (0.80–0.84) 0.84  0.15
Moderate COPD 0.80 (0.79–0.81) 0.73  0.23
Severe COPD 0.77 (0.77–0.78) 0.74  0.25
Very severe COPD 0.74 (0.74–0.76) 0.52  0.26
Exacerbations [15]
Nonsevere 0.01
Severe 0.08
CI, confidence interval; COPD, chronic obstructive pulmonary
disease; GOLD, Global Initiative for Chronic Obstructive Lung
Disease; Ind, indacaterol.and 3) cost of exacerbation. The acquisition cost (Table 3) for
tiotropium was obtained from Ministerio de proteccio´n social de la
republica de Colombia 2011 [20] and that for LABA/ICS from
Ministerio de proteccio´n social de la republica de Colombia 2008 [21]
and corrected to 2011 [22]. Costs of COPD maintenance (Table 4)
were based on 30 clinical records from Teleton University Hospi-
tal’s pulmonary rehabilitation program in 2010 and consisted of
other medications, cost of visits, cost of radiologic tests, and cost
of laboratory tests. The cost of exacerbation was dependent on
severity. Nonsevere exacerbations consisted of ambulatory and
emergency events, but no hospitalizations. Cost of ambulatory
events was based on medication costs [21], and the costs of visits
were derived from the Teleton University Hospital’s pulmonary
rehabilitation program, whereas the frequencies were based on
the GOLD strategy and expert opinion. The cost of emergency
visits was based on 144 billing records. Cost of severe exacerba-
tions consisted of ambulatory emergency events and hospitaliza-
tions. The costs of ambulatory events and emergency visits were
estimated in the same way as for nonsevere exacerbations. The
cost of hospitalization was based on 29 billing records in 2010.
Costs were converted to US dollars with the following exchange
rate: 1 USD ¼ COP 1771.13, as on April 20, 2012 [23].
The base-case CE analysis was performed with a 5-year time
horizon, and both cost and effect outcomes were discounted with
a 5% rate. The model predicted the potential gains in LYs and
QALYs, as well as costs incurred. Both one-way sensitivity
analysis (OWSA) and probabilistic sensitivity analyses (PSAs)
were conducted. In the one-way sensitivity analysis, each vari-
able in the model was set to the outer limits of the confidence
interval. The PSA is a stochastic analysis, where all parameter
uncertainty in the model is evaluated at once. One thousand
model iterations were performed, varying all model parameters
each time carrying second order uncertainty, within logical
ranges. Costs were varied according to a gamma distribution,
utilities by a beta distribution, rate ratios by a log-normal
distribution, and patient transitions by a Dirichlet distribution.
A budget impact analysis with a 3- and 5-year horizon was
performed, considering only the cost of the four long-acting
inhaled products used in the treatment of COPD in Colombia.
The size of the eligible population was estimated in the following
way. The adult population 40 years or older in Colombia was
14,958,285 in 2012 [2], with a COPD prevalence of 8.9% [1]. Only
12.6% [1] of those suffering from COPD, however, have been
diagnosed; further, this analysis only considers those who have
a severity of GOLD 2 or worse, which is only 31.1% of all
diagnosed patients with COPD [1]. Based on observations in a
Swiss study [24] on the compliance to GOLD strategy, it is
estimated that 60.0% of the patients with a severity of 2 to 4 will
Table 3 – Cost of interventions.
Ind Tio For/Bud Sal/Flu
Brand name Onbrez Breezhaler Spiriva Symbicort Seretide
Dosage (mg) 150 18 9/320 50/500
Price (COP) [28,29] 115,500 103,285 158,490 135,084
Package size 30 30 60 60
Number of dosages per day 1 1 2 2
Price per day (COP) 3850 3443 5283 4503
Price per day (US $) 2.17 1.94 2.98 2.54
Note. 1 USD ¼ COP 1771.13 [23].
COP, Colombian pesos; For/Bud, formoterol/budesonide; Ind, indacaterol; Sal/Flu, salmeterol/fluticasone; Tio, tiotropium; USD, US dollar.
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patient population of 31,301 in 2012, with an annual increase of
1.156% (Table 5).Results
Base-Case Analysis Versus FDC
Within a 5-year time horizon, indacaterol 150 mg was found to be
dominant (i.e., less costly and more effective) against both salme-
terol/fluticasone and formoterol/budesonide per LY and QALY
gained. The cost savings against both salmeterol/fluticasone and
formoterol/budesonide corresponded to US $411 and US $908,
respectively. The estimated gains in LYs were 0.003 and 0.007
compared with salmeterol/fluticasone and formoterol/budesonide,
respectively. The corresponding QALY gains were 0.004 and 0.010.
The greater increase in incremental QALYs compared with LYs was
a consequence of the patient composition at baseline, influencing
the amount of time patients spent in the different GOLD stages.
Additional sensitivity analysis demonstrated that the gain in
incremental QALYs was higher than LYs for a patient population
with moderate or severe COPD at baseline, in contrast to a patient
population with a very severe COPD at baseline.
Sensitivity Analysis Versus FDC
The PSA was run for the comparisons versus salmeterol/fluticasone
and formoterol/budesonide. The results of the 1000 iterations were
plotted in Figure 2, with 65.7% of the simulations indicating indaca-
terol to be less costly and more effective compared with salmeterol/Table 4 – Costs of maintenance and exacerbations per GOLD st
Mild
Annual maintenance cost
Other medications 179
Cost of visits 175
Cost of radiologic 128
Cost of laboratory 115
Exacerbations Nonsevere
Ambulatory visit (per event) 18
Emergency visit (per event) 397
Hospitalization (per event) –
For/Bud, formoterol/budesonide; GOLD, Global Initiative for Chronic Obstr
Tio, tiotropium.
* Based on 144 Clinical records from Teleto´n University Hospital pulmonfluticasone and 94.2% of the simulations indicating the same with
indacaterol compared with formoterol/budesonide. For 100% of the
simulations, indacaterol was less costly than comparators.Scenario Analyses
One scenario tested the baseline composition of the starting
cohort (i.e., disease severity and mean) based on the PREPOCOL
cohort. This cohort consists of less severe patients than the
indacaterol trial and therefore has less capacity to benefit as
compared with a more severe population. Consequently, as
expected, this scenario resulted in an increase in cost savings
whereas the incremental QALYs gained decreased.
A second analysis was carried out versus tiotropium. The
incremental cost-utility ratio was US $2584 per QALY after 5 years,
well below a threshold of US $5274 (COP 9,340,940, equal to the per-
capita GDP). The cost per LY gained was similar with US $2899.
Indacaterol was found to be dominant against tiotropium if the US
$2.17 per-day price was lowered by 1.4% to US $2.14. Over a 5-year
time horizon, 47.2% of the combined simulations against tiotro-
pium fell within the northeast quadrant of the CE plot, meaning
that it requires evaluation of its CE to see whether it meets
willingness-to-pay threshold requirements (US $5274). Another
0.7% fell in the northwest quadrant, suggesting that indacaterol
was dominated; 0.4% fell in the southwest quadrant, indicating the
proportion of iterations that were inferior (i.e., less cost and fewer
QALYs); while the remaining 51.4% fell within the southeast
quadrant, where the scenario was dominant. A CE acceptability
curve was created on the basis of PSA simulation, found in Figure 3.
There was a 78% probability that the ICUR would fall below USage in US $.
GOLD stage
Moderate Severe Very severe
179 205 2810
175 222 315
128 328 477
115 127 109
Severe
18
368
1963
uctive Lung Disease; Ind, indacaterol; Sal/Flu, salmeterol/fluticasone;
ary rehabilitation program. 2010.
Table 5 – Budget impact analysis over 3 y.
Year 1 Year 2 Year 3
Wo W† Wo W† Wo W†
Patient population 31,301z 31,663y 32,029y
GOLD 2 (87.1%)
Ind 0 7,360 0 7,445 0 7,531
Tio 11,449 6,815 11,581 6,893 11,715 6,793
For/bud 7,905 6,542 7,996 6,618 8,089 6,694
Sal/flu 7,905 6,542 7,996 6,618 8,089 6,694
GOLD 3 (11.3%)
Ind 0 670 0 677 0 685
Tio 1,339 881 1,355 891 1,370 901
For/bud 889 987 909 998 919 1,010
Sal/flu 889 987 909 998 919 1,010
Tio þ FDCk 194 0 196 0 198 0
Tio þ FDCz 194 0 196 0 198 0
GOLD 4 (1.7%)
Ind 0 47 0 47 0 48
Tio 145 130 147 131 148 133
For/bud 122 106 123 107 125 109
Sal/flu 122 106 123 107 125 109
Tio þ FDCk 65 65 66 66 66 66
Tio þ FDCz 65 65 66 66 66 66
Difference in cost in US $ (W Wo)
GOLD 2 197,016 199,293 201,597
GOLD 3 282,031 285,291 288,589
GOLD 4 5,378 5,440 5,503
Total 484,424 490,024 495,689
FDC, fixed-dose combination; For/Bud, formoterol/budesonide; GOLD, Global Initiative for Chronic Obstructive Lung Disease; Ind, indacaterol;
Sal/Flu, salmeterol/fluticasone; Tio, tiotropium; W, with; Wo, without.
* Analysis without Ind on the market.
† Analysis with Ind on the market.
z Population is estimated by 14,958,285  8.9%  12.6%  31.1%  60% ¼ 31,301.
y Increased with 1.156% from previous year.
k For/Bud.
z Sal/Flu.
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fall below US $15,821 (three times the per-capita GDP).
Budget Impact Analysis
The budget impact model forecasted that the introduction of
indacaterol in Colombia would result in a cost saving of US $1.47
million after 3 years and US $2.48 million after 5 years. The
amount, however, of cost savings was very much dependent on
whether indacaterol replaced the more expensive salmeterol/
fluticasone, formoterol/budesonide, and triple therapy or the less
expensive tiotropium. In Table 5, the cost savings are presented
by GOLD stage for the first 3 years. Indacaterol was forecasted to
mainly replace tiotropium and to a lesser extent salmeterol/
fluticasone and formoterol/budesonide in patients with stage 2
severity on the GOLD scale. In GOLD 3, indacaterol was predicted
to replace triple therapy, leading to substantial cost savings.
Results were affected by the assumed proportion of salme-
terol/fluticasone and formoterol/budesonide usage. In the base
case, formoterol/budesonide was assumed to have 50% market
share, leading to cost savings of US $2.48 million. A 100% market
share for formoterol/budesonide would result in US $3.54 million
savings, while a 100% market share for salmeterol/fluticasone
would result in a US $1.42 million cost saving after 5 years.Discussion
Our analyses demonstrated that indacaterol was an effective and
cost-saving treatment option for patients with COPD in Colombia
compared with both salmeterol/fluticasone and formoterol/bude-
sonide. The PSA [2], however, showed that there is substantial
uncertainty around the incremental gain in QALYs for both
analyses. In contrast, there was much less uncertainty around
the cost savings. Part of the uncertainty in the results is explained
by the use of the mixed treatment comparison results, which were
adjusted for the presence of two covariates; these results, while
allowing the consideration of smoking status and disease severity,
resulted in an increased CrI when computing the PSA results. In an
alternative scenario using mixed treatment comparison results
unadjusted for any covariates, the point estimate results were
similar but the PSA results showed a slightly narrower range of
QALY estimates, and were contained entirely in the southeast
quadrant. There was a trade-off between selecting the analysis
with less uncertainty but no covariate adjustment for patient
characteristics and the analysis with more uncertainty but con-
sideration of patient characteristics; the base case chose the latter,
which is also a more conservative estimation of indacaterol’s
potential clinical benefit. These results were sensitive to changes
Fig. 2 – Cost-effectiveness plane, indacaterol versus salmeterol/fluticasone (boxes) and indacaterol versus formoterol/
budesonide (circles) based on the base-case analysis. For/Bud, formoterol/budesonide; NE, northeast; NW, northwest; QALY,
quality-adjusted life-year; Sal/Flu, salmeterol/fluticasone; SE, southeast; SW, southwest.
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Furthermore, the analysis against tiotropium showed that indaca-
terol would have a 78% probability of having an ICUR of less than or
equal to a willingness to pay of US $5274 (three times the
Colombian per-capita GDP). These results were found to be most
sensitive to changes in baseline composition, thus COPD severity.
A number of limitations were identified in this model. First, this
analysis did not consider a difference in exacerbations between
indacaterol and LABA/ICS. Exacerbations were not the primary end
point of the trials included in the NMA and therefore were not
reported [12]. Exacerbations, however, have a small impact on the
total result in comparison to changes in FEV1. As an example, if one
assumed no difference in exacerbation between indacaterol and
tiotropium, the incremental costs increased by US $6 and the
number of QALYs gained was reduced by 0.0002. The inclusion of
exacerbation rates in the comparison of indacaterol versus LABA/
ICS would therefore have only minor impact.0%
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GDP, gross domestic product; QALY, quality-adjusted life-year.Second, QALYs have been used as the outcome for the main
analysis; it is a limitation that all values, that is, both value set and
decrements, were based on a European population. Incremental
QALY results in this model showed that the differences among
comparators were small. The impact in quality of life of symptoms
such as cough, breathlessness, and dyspnea, however, was difficult
to capture as a change in utility by using a nondisease-specific
measure such as the EQ-5D questionnaire. However, it should be
remembered that this study was based on direct clinical trial data
and for this reason external applicability is unknown in the absence
of real-world evidence. Maintenance and exacerbation costs
included in the analysis were obtained from a single institutional
source, and as such further actualization of the model results with
additional sources of costs will improve its external validity.
Comorbidities commonly associated with COPD were not
analyzed in terms of additional costs and risks because these
patients were excluded from the clinical trials. It was not likely.000 12.000 14.000 16.000 18.000 20.000
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applied to all treatment arms. Real-life adherence and compli-
ance were not included, as we do not have a reason to believe
that there would be a difference between the treatment arms.
In addition, the efficacy results from the intention-to-treat
population would account for these parameters.
Another assumption that introduced uncertainty in the model
was the 5-year projection from 6-month duration clinical trials.
However, considering the limitations in conducting long-term
clinical trials, not just for COPD, projections to 5-year time
horizons are a common practice in pharmacoeconomic modeling
studies for chronic diseases.
Finally, this analysis excluded any impact of the use of ICS in
patients for whom it is not indicated. There is some evidence to
suggest that long-term usage of high-dose LABA/ICS results in
loss of bone mineral density at the femoral neck and lumbar
spine [25]. In fact, each 500-mcg increase in beclomethasone dose
or equivalent has been associated with a 9% increased risk of
fractures in patients with COPD [26]. An increased risk of diabetes
onset and progression in patients receiving high doses of ICS has
also been found [27]. In addition, there is an increased risk of
pulmonary infections such as pneumonia [28] and tuberculosis
[29,30]. This latter risk is particularly important in Colombia, a
country with a high prevalence of tuberculosis. Consideration
of these adverse effects may lead to a more accurate assessment
of the value of introducing indacaterol to replace FDC products.
In conclusion, the results indicate that by replacing salme-
terol/fluticasone or formoterol/budesonide with indacaterol,
there are probable cost savings for the Colombian health care
system. This is an important finding as the prevalence of COPD
(as assessed by spirometry) in Colombia is estimated to be 8.9% of
those aged 40 years or older. Incremental CE results versus
tiotropium showed that indacaterol had a high probability
of demonstrating CE considering the current Colombian
willingness-to-pay threshold (US $5274). If the Colombian health
system is considering newer inhaled treatments for COPD, the
inclusion of indacaterol in the health benefit plan appears
justified not only on the basis of clinical results but also
economically on the basis of the analysis presented.
Source of financial support: Novartis funded this study.
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